Atlas Trials

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Clinical trial NCT02452008 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02452008
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer
Start date
2016-05-03
Primary completion
2025-12-08
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.